Výsledky vyhledávání

Supplementary Data from Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Autor: Hugh M. Davis, Birge Berns, Qun Jiao, Uma Prabhakar, Thomas Puchalski

Supplementary Data from Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c5641c94a6071a2cb90a8dc48217c3f
https://doi.org/10.1158/1078-0432.22441839.v1

Zobrazit plný text záznamu

Data from Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Autor: Hugh M. Davis, Birge Berns, Qun Jiao, Uma Prabhakar, Thomas Puchalski

Purpose: Interleukin-6 (IL-6) induces tumor growth, invasion, metastasis, and angiogenesis. Siltuximab (CNTO 328) is a chimeric, murine-human monoclonal antibody that specifically binds human IL-6 with high affinity. C-reactive protein (CRP) can be a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e896633d34ddccfbbe1b23ca2f2469f
https://doi.org/10.1158/1078-0432.c.6518742.v1

Zobrazit plný text záznamu

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Autor: George Wang, Shobha Seetharam, Birge Berns, Kyri Papadopoulos, Thomas A. Puchalski, Peter C.C. Fong, Shahneen Sandhu, Frances R. Balkwill, Christina Messiou, Anthony W. Tolcher, Amita Patnaik, David Olmos, Johann S. de Bono, Brenda Tromp

Publikováno v: Cancer Chemotherapy and Pharmacology. 71:1041-1050

The CC-chemokine ligand 2 (CCL2) is highly expressed in various malignancies and promotes carcinogenesis. Blocking CCL2 has preclinical antitumor activity. A phase 1 trial of carlumab (CNTO 888), a human anti-CCL2 IgG1κ mAb, was conducted to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6124c0d40b0540be1b297701b97b167b
https://doi.org/10.1007/s00280-013-2099-8

Zobrazit plný text záznamu

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

Autor: Birge Berns, Thomas A. Puchalski, Uma Prabhakar, Qun Jiao, Hugh M. Davis

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 16(5)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21954017f82b333c3b0a221322b83b1b
https://pubmed.ncbi.nlm.nih.gov/20179212

Zobrazit plný text záznamu

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors

Autor: Birge Berns, Shahneen Sandhu, Anthony W. Tolcher, Amita Patnaik, Martin Forster, Christina Messiou, Frances R. Balkwill, Brenda Tromp, J.S. de Bono, Kyri Papadopoulos

Publikováno v: Journal of Clinical Oncology. 28:2548-2548

2548 Background: The chemokine CCL2 is highly expressed in various malignancies, and is implicated in tumor angiogenesis, proliferation, and metastasis. CCL2 orchestrates tumor-associated macrophag...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e087ecb0e45c40b2ba31abb663169c5
https://doi.org/10.1200/jco.2010.28.15_suppl.2548

Zobrazit plný text záznamu

Abstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors

Autor: Birge Berns, Thomas A. Puchalski, Susan Hoare, Peter C.C. Fong, Shahneen Sandhu, Brenda Tromp, Amita Patnaik, J. De-Bono, Christina Messiou, Frances R. Balkwill, David Olmos, Kyri Papadopoulos, Anthony W. Tolcher

Publikováno v: Molecular Cancer Therapeutics. 8:A102-A102

Background: The chemokine CCL2 / MCP-1 is highly expressed in multiple tumor types. Overexpression of CCL2 is associated with more advanced disease and a worse prognosis in some cancers. CCL2 plays a pivotal role in recruitment of tumor-associated ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::70ed9603d13c4c5e6a866e8e06480524
https://doi.org/10.1158/1535-7163.targ-09-a102

Zobrazit plný text záznamu

First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

Autor: Thomas A. Puchalski, J. De-Bono, Peter C.C. Fong, Birge Berns, S. Frentzas, Brenda Tromp, Anthony W. Tolcher, Amita Patnaik, Shahneen Sandhu, Kyri Papadopoulos

Publikováno v: Journal of Clinical Oncology. 27:e13500-e13500

e13500 Background: The chemokine CCL2 promotes angiogenesis, tumor proliferation, migration and metastasis through PI3K and NFkB signaling. CNTO 888 is a human IgG1κ monoclonal antibody with high binding affinity for CCL2 and documented preclinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bda3105deb53f68ccc3384ade32e8a13
https://doi.org/10.1200/jco.2009.27.15_suppl.e13500

Zobrazit plný text záznamu

Mikromethode zum Nachweis erythrozyt�rer Antigene an Blutspuren

Autor: H. Kern, J. Lötterle, Birge Berns

Publikováno v: Zeitschrift f�r Rechtsmedizin. 96

Um den Absorptions-Elutions-Test auch noch mit sehr kleinen Blutspuren durchfuhren zu konnen, wurde ein Verfahren entwickelt, bei dem die Reaktionsschritte wahrend der Absorptions- und Elutionsphase in sogenannten Beckman-Tubes (0,4 ml Inhalt) erfolg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea33c45db063f8a415c2f002abc45bc7
https://doi.org/10.1007/bf00200276

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání